ERYTECH announces positive safety review for eryaspase in its Phase 2 study in pancreatic cancer

Post author:admERY
Post published:July 20, 2015
Post category:Newsroom

ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer.

You Might Also Like

ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC

ERYTECH Announces the Availability of its Half-Year Financial Report 2021

ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy